Oppenheimer Downgrades Turning Point Therapeutics Inc. (TPTX) to Perform Amid Takeover
Tweet
Share
E-mailGet Alerts TPTX Hot Sheet
Price: $76.01 --0%
Rating Summary:
5 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 33 | Down: 45 | New: 4
Rating Summary:
5 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 33 | Down: 45 | New: 4
Join SI Premium – FREE
Oppenheimer analyst Matthew Biegler downgraded Turning Point Therapeutics Inc. (NASDAQ: TPTX) from Outperform to Perform following takeover.
For an analyst ratings summary and ratings history on Turning Point Therapeutics Inc. click here. For more ratings news on Turning Point Therapeutics Inc. click here.
Shares of Turning Point Therapeutics Inc. closed at $34.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades Legal & General Group PLC (LGEN:LN) (LGGNF) to Sell
- Nomura/Instinet Downgrades Pentamaster Corp. Bhd (PENT:MK) to Neutral
- Wells Fargo Downgrades Genius Sports Ltd. (GENI) to Equal Weight
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
